Abstract 651P
Background
XNW27011 is a novel claudin 18.2(CLDN 18.2)-targeting ADC with the TMALIN® linker, a proprietary TOP1i payload more potent than Dxd, and homogeneous DAR of 8. Here we report the preliminary results from the dose escalation phase of the first in human, multi-center, open-label, phase I/II study of XNW27011 in patients (pts) with locally advanced and/or metastatic solid tumors who have failed or are intolerant to standard therapies.
Methods
XNW27011 was given starting from 0.6 mg/kg (Q3W, IV) in an accelerated titration followed by 3+3 escalation scheme. The primary objective of dose escalation phase was to determine MTD.
Results
As of Apr. 15, 2024, 16 pts were enrolled in 6 dose cohorts from 0.6 to 6.0 mg/kg, including 11 GC/GEJC, 2 OC, 2 PC, and 1 duodenal periampullary adenocarcinoma (ECOG 0-1, majority of pts received ≥3 lines of prior therapy). 12 pts had various levels of CLDN18.2-expression (≥1%, IHC ≥ 1+). During DLT period, the most common AEs were nausea and vomiting, followed by white blood cell decrease, neutrophil decrease and anemia. No ≥ grade 3 TRAEs were observed below 4.8 mg/kg during DLT period. No ILD or MMAE-related ocular AEs and peripheral neuropathy were observed. One patient experienced DLT at 6.0 mg/kg. The table summarized efficacy in 14 evaluable pts. Efficacy was observed even at doses as low as 0.6 mg/kg. Prior PD-1 immunotherapy, irinotecan or CLDN18.2 antibody therapy seemed not to impact efficacy. Table: 651P
Efficacy outcomes
All tumor (n=14) | CLDN18.2+ * tumor (n=11) | CLDN18.2+ * GC/GEJC 1 (n=8) | CLDN18.2+ * OC 2 (n=2) | CLDN18.2+ * PC 3 (n=1) | |
ORR | 50% (7/14) | 64% (7/11) | 63% (5/8) | 50% (1/2) | 100% (1/1) |
DCR | 86% (12/14) | 100% (11/11) | 100% (8/8) | 100% (2/2) | 100% (1/1) |
*CLDN18.2+: any level of CLDN18.2 expression, defined as CLDN 18.2 _1%, IHC_1+; GC/GEJC1: gastric cancer/gastroesophageal junction cancer; OC2: ovarian cancer; PC3: pancreatic cancer
XNW27011 has shown similar concentration-time curves of ADC and TAb, long T1/2= 5-9 days, and extremely low free payload at all tested doses (Cmax of 0.253 to 1.65 ng/mL corresponding to 0.6-6.0 mg/kg doses).
Conclusions
XNW27011 demonstrated a favorable safety profile with large therapeutic window, superior preliminary efficacy across tumor type and CLDN 18.2 expression level, and excellent PK properties including low payload plasma exposure. The study is ongoing with the expansion phase being initiated in multiple tumor cohorts.
Clinical trial identification
Editorial acknowledgement
Xiujing Emma Feng from Evopoint Biosciences USA, Inc.
Legal entity responsible for the study
Evopoint Biosciences Co. Ltd.
Funding
Evopoint Biosciences Co. Ltd.
Disclosure
H. Zhao, Y. Hu, H. Wei, Y. Zhao, Y. Wang, Q. Shi, J. Li: Financial Interests, Personal, Full or part-time Employment: Evopoint Biosciences Co. Ltd.; Financial Interests, Personal, Stocks/Shares: Evopoint Biosciences Co. Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01